ONE YEAR DATA FROM THE SONIC STUDY: A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING INFLIXIMAB AND INFLIXIMAB PLUS AZATHIOPRINE TO AZATHIOPRINE IN PATIENTS WITH CROHN'S DISEASE NAIVE TO IMMUNOMODULATORS AND BIOLOGIC THERAPY

(1) Hepatogastroenterology, Centre Hosp Universitaire de Lille, Lille, France

(2) Int Med, U Hosp Gasthuisberg, Leuven, Belgium

(3) U Hosp Vienna, Vienna, Austria

(4) Evangelismos Hosp, Athens, Greece

(5) Medicine, Mt Sinai Med Center, New York, United States

(6) Shaare Zedek Medical Center, Jerusalem, Israel

(7) Int Med, Mt Sinai Medical Center, New York, United States

(8) Gastroenterology, Imelda Ziekenhuis, Bonheiden, Belgium

(9) W W Med Affairs

(10) Clinical Research

(11) Biostatistics, Centocor, Inc, Horsham, United States

(12) Erasmus MC, Rotterdam, Netherlands

(13) Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States



This item was part of the Anti TNF therapy in IBD: Current to future session at Gastro 2009 UEGW/WCOG London (17th UEGW)

This item can be cited as: Gut 2009; 58 (Suppl II) A69

You may be interested in:

New therapeutic strategies for IBD
English, Presentation, Clinical aspects, Medical management, Colon, Inflammatory bowel disease, Small intestine, 2010

Categorisation:

  • Format
    • Abstract
  • Language
    • English
  • Year
    • 2009